Inspire Says INS365 NDA Filing Not Far Off; Stock Jumps 53%

Inspire Pharmaceuticals Inc. said following a productive meeting with the FDA, it has decided to compile existing data from three trials of its dry-eye product, INS365 Ophthalmic, and submit it for regulatory approval. (BioWorld Today)